CBD shows promise in helping heavy drinkers stay off alcohol

NCT ID NCT05860699

Recruiting now Symptom relief Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding cannabidiol (CBD) to standard alcohol detox treatment helps people with severe alcohol use disorder stay sober longer. About 210 adults will receive either CBD or a placebo for 11 days during a hospital stay. Researchers will check if participants remain abstinent for up to 6 weeks after leaving the hospital.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE ALCOHOL USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse alcohol dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE ALCOHOL USE DISORDER (DSM 5)

Contacts and locations

Locations

CHU Gabriel Montpied
RECRUITING

Clermont-Ferrand, Clermont Ferrand, 63000, France
Hôpital Albert Chenevier
RECRUITING

Créteil, Albert Chenevier, 94000, France
Hôpital Antoine Béclère
NOT_YET_RECRUITING

Clamart, Clamart, 92140, France
Hôpital Avicenne
NOT_YET_RECRUITING

Bobigny, France, 93000, France
Hôpital Bichat
WITHDRAWN

Paris, Paris, 75018, France
Hôpital Cochin
NOT_YET_RECRUITING

Paris, Paris, 75014, France
Hôpital Fernand Widal
RECRUITING

Paris, France, France, France
Hôpital Hôtel-Dieu
NOT_YET_RECRUITING

Paris, Paris, 75004, France
Hôpital Louis Mourier
WITHDRAWN

Colombes, Colombes, 92700, France
Hôpital René Muret
RECRUITING

Sevran, Sevran, 93270, France
Hôpital Saint Anne
RECRUITING

Paris, Paris, 75014, France
Hôpital la Colombière
NOT_YET_RECRUITING

Montpellier, 34090, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.